Core Insights - Sanara MedTech Inc. is participating in the TD Cowen 46th Annual Health Care Conference from March 2 – 4, 2026, with a presentation scheduled for March 3 at 9:10 a.m. Eastern Time [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [3] - The company markets surgical products primarily in the North American surgical tissue repair market, including CellerateRX Surgical Activated Collagen Powder, BIASURGE Advanced Surgical Solution, and FORTIFY TRG Tissue Repair Graft [3] - Sanara aims to be an innovative provider of effective surgical solutions and is committed to expanding its product offerings for patients in the United States [3]

Revenue Projections - Net revenue for Q4 2025 is expected to be between $27.2 million and $27.7 million, representing a year-over-year increase of approximately 3% to 5% compared to $26.3 million in Q4 2024[4]. - Full year 2025 net revenue is projected to be in the range of $102.7 million to $103.2 million, reflecting a growth of approximately 19% compared to $86.7 million in 2024[4]. - Excluding BIASURGE sales from Q4 2024, net revenue for Q4 2025 is expected to increase approximately 11% to 13% year-over-year[4]. - Full year 2026 net revenue is expected to range from $116 million to $121 million, indicating growth of approximately 13% to 17% compared to the midpoint of the expected net revenue for 2025[5]. - The expected net revenue growth for 2026 is primarily driven by sales of soft tissue products[5]. Financial Position - The company had cash of approximately $16.6 million and long-term debt of $46.0 million as of December 31, 2025, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024[4]. Product Development and Market Strategy - The company plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance[4]. - BIASURGE received an Innovative Technology contract from Vizient, expanding access to the product at contracted pricing effective January 1, 2026[4]. - The company aims to enhance its sales and distribution network while expanding its product portfolio through initiatives with Biomimetic Innovations Ltd[5]. - The company is positioned as a pure play surgical business, targeting sustainable long-term growth in the multi-billion-dollar surgical solutions market[5].

Core Viewpoint - Sanara MedTech Inc. reported preliminary financial results for Q4 and full year 2025, indicating strong growth and provided financial guidance for 2026, projecting continued revenue growth driven by surgical products [1][4]. Financial Results - Preliminary net revenue for Q4 2025 is expected to be between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5% compared to $26.3 million in Q4 2024 [5]. - For the full year 2025, net revenue is projected to be in the range of $102.7 million to $103.2 million, marking a growth of approximately 19% compared to $86.7 million in 2024 [5]. - Excluding BIASURGE sales from Q4 2024, the adjusted net revenue for Q4 2025 is expected to increase by approximately 11% to 13% year-over-year [5][13]. Financial Guidance - The company anticipates full year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to the midpoint of the expected net revenue for 2025 [4][6]. - The growth in 2026 is expected to be primarily driven by sales of soft tissue products [6]. Operational Highlights - The company secured a new contract with Vizient, enhancing access to BIASURGE products at contracted pricing, effective January 1, 2026 [4][6]. - Sanara plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance [5][6]. Cash and Debt Position - As of December 31, 2025, the company reported cash of approximately $16.6 million and long-term debt of $46.0 million, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024 [5].

Core Insights - Sanara MedTech's BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient, indicating its potential to improve healthcare outcomes and reduce costs in the surgical market [1][3][4] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical market [7][8] - The company offers a range of surgical products, including BIASURGE, CellerateRX Surgical Activated Collagen Powder, and FORTIFY TRG Tissue Repair Graft, among others [8] Product Details - BIASURGE is a no-rinse irrigation solution designed for efficient surgical cleansing, featuring an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms [5][6] - The product is optimized for pH, viscosity, and osmolality to ensure maximum performance while maintaining safety and effectiveness [5] - BIASURGE enhances surgical precision and visibility by maintaining a cleaner operative field, supporting infection-control strategies [6] Contract Significance - The Innovative Technology contract allows Vizient's extensive network of healthcare facilities to access BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026 [3][4] - The contract was awarded based on recommendations from hospital experts, highlighting BIASURGE's unique benefits over existing market products [3][4]

Core Insights - Sanara MedTech Inc. plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. market in Q1 2027, following FDA clearance [1][2] - OsStic has received Breakthrough Device Designation from the FDA, indicating its potential to improve treatment for serious conditions [2] - The product is expected to be the first bone bioadhesive in the U.S. utilizing phosphoserine, α-TCP, and calcium silicate, offering significant advantages over traditional methods [2][3] Product Development and Regulatory Milestones - Sanara and Biomimetic Innovations Ltd (BMI) have achieved significant milestones in product development, clinical trials, and regulatory processes throughout 2025 [3] - The U.S. Patent and Trademark Office granted a patent for OsStic, ensuring protection of its key ingredients and applications until at least 2037 [3][6] - The partnership between Sanara and BMI includes an exclusive license and distribution agreement, enhancing Sanara's market position in orthopedic care [5][6] Market Need and Innovation - OsStic addresses critical limitations in current provisional fixation techniques, providing forty times stronger bonding than traditional calcium phosphate bone cement [2][3] - The product aims to meet the unmet clinical needs in complex joint reconstruction, offering a paradigm shift in treating previously non-repairable fractures [3] - Sanara's commitment to innovation is reflected in its collaboration with BMI to introduce OsStic as a new standard in bone bioadhesives [4]

Core Insights - Shares of Sanara MedTech Inc. (SMTI) have sharply declined following the release of the company's Q3 earnings, with a nearly 40% drop for the year [1] Company Performance - The surgical segment of Sanara MedTech has been fast-growing and profitable, but this growth has been overshadowed by recent stock performance [1]

Company Overview - Shares of Sanara MedTech Inc. (SMTI) have declined sharply, down nearly 40% for the year following the release of the company's Q3 earnings [1] Financial Performance - The company's fast-growing and profitable surgical segment has been overshadowed, indicating potential underlying issues despite growth in this area [1]

Core Insights - Holzer & Holzer, LLC is investigating whether Sanara MedTech Inc. complied with federal securities laws following the announcement of a strategic realignment that included discontinuing operations of Tissue Health Plus to improve operating efficiency and reallocate resources to its core surgical business [1] - The announcement led to a decline in Sanara's stock price [1] Company Overview - Sanara MedTech Inc. is publicly traded on NASDAQ under the ticker SMTI [1] - The company is focusing on enhancing its core surgical business by discontinuing less efficient operations [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into Sanara MedTech Inc. regarding potential violations of federal securities laws, indicating concerns about the company's compliance and the impact on investors [1]. Company Summary - Sanara MedTech Inc. (NASDAQ: SMTI) is currently under scrutiny for possible legal issues that may affect its investors [1]. - The investigation is aimed at assessing the extent of any violations and the implications for shareholders who may have incurred losses [1].

Core Viewpoint - Sanara MedTech Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1]. Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1]. - The announcement regarding the investigation was made on November 11, 2025, after market hours [1].